In our clinical cohort of 734 CRC patients as well as in a validation cohort of 376 CRC patients, this extended PREMM5 model not only identified PMS2 mutation carriers more accurately, its overall performance was also better than the original PREMM5 model and the MMRpredict model. Here, PMS2 is linked to colorectal carcinoma.